Navigation Links
Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Date:9/8/2010

nts.  Starting with a deep understanding of the mechanisms by which cancer develops, grows and spreads, as well as identifying the right science early in the discovery process, the company employs innovative approaches to bring the right medicines to the right patients.  There are currently more than 10 compounds in development across a broad scientific platform, including cytotoxic, antimitotic, anti-angiogenic agents, antivascular agents, monoclonal antibodies and cancer vaccines, as well as supportive care therapies.  Four of these compounds are now being investigated in Phase 3 clinical studies aimed at multiple solid and hematologic tumors.

About sanofi-aventisSanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.  Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Regeneron Pharmaceuticals, Inc.Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Forward-Looking Statements: sanofi-aventisT
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... The Global Breast Pumps Market is ... an estimated CAGR of 7.6% from 2014 to 2020, according ... of innovative technologies including hand free breast pumps, growing women ... advantages of breast milk are expected to drive breast pump ... untapped growth opportunities in emerging markets such as ...
(Date:7/7/2015)... China , July 7, 2015 /PRNewswire/ -- Mindray ... a leading developer, manufacturer and marketer of medical ... acquire the remaining stake in Wuhan Dragonbio Surgical ... Dragonbio is a domestic medical ... and other surgical products. Prior to today,s announcement, ...
(Date:7/7/2015)... July 7, 2015 EnteroMedics Inc. (NASDAQ: ... use neuroblocking technology to treat obesity, metabolic diseases, and ... announced public offering of 32,000,000 units. Each unit consists of ... warrant to purchase one share of common stock at ... purchase of units in the offering would result in ...
Breaking Medicine Technology:Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
(Date:7/7/2015)... ... 07, 2015 , ... Leading healthcare consulting firm Hammes Company ... Vice President, heading the firm’s Healthcare Advisory Services division. , Mr. Warden will ... providers’ needs in ways that strengthen their position in the marketplace. The Healthcare ...
(Date:7/7/2015)... ... ... a reputable source of authentic tickets for the 2015 CONCACAF Gold Cup Group A matches ... Stadium. , The 2015 CONCACAF Gold Cup is now upon us as Group A ... soil, will kick off in Frisco, CA from the Toyota Stadium and will feature two ...
(Date:7/7/2015)... ... July 07, 2015 , ... Greatist today announced the ... helps active people find the most fun activities to do with friends. , The ... It also increases Greatist’s opportunity for events, e-commerce, and brand partnerships. , “I’ve been ...
(Date:7/7/2015)... N.J. (PRWEB) , ... July ... ... CTLT), the leading global provider of advanced delivery technologies and development solutions ... signed an exclusive licensing agreement with Excelimmune, Inc. to access its antibody ...
(Date:7/7/2015)... ... July 07, 2015 , ... Healthpointe is ... team. Dr. Alupay, an anesthesiologist and pain management specialist, will be evaluating and treating ... as neurological conditions. , After receiving his Bachelor of Science in Biology from the ...
Breaking Medicine News(10 mins):Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 2Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3
... CHICAGO, Sept. 18 As economic, social and political ... state,s leading provider of addiction treatment services is expanding its ... afford expensive clinics but also fail to qualify for government-funded ... a 41-year-old non-profit organization, serves more than 29,000 patients in ...
... feelings of isolation remains unclear , FRIDAY, Sept. 18 (HealthDay ... suicide and rural communities that have higher numbers of bars. ... mean more suicides because it does not show cause and ... percent are alcoholics, according to background information in a news ...
... , SAN FRANCISCO, Sept. 18 VIA ... focused on the development of compounds for the treatment of ... 2009, it received a deficiency letter from the NASDAQ Stock ... the minimum $1.00 per share bid price requirement for continued ...
... , BROOMFIELD, Colo., Sept. 18 Accera, Inc., ... today announced today that it will present at the UBS Global ... , Steve Orndorff, Ph.D., founder, president and CEO, ... Axona (TM) on Monday, September 21 at 11:30 a.m. EDT. ...
... , , WASHINGTON, Sept. 18 ... plan by Senate Finance Chairman Max Baucus, DMLR Chairman Stuart L. ... "The plan released by Senator Baucus is inadequate in addressing the ... and Democrats in the Congress, health care policy experts, opinion leaders, ...
... , BELLEVUE, Wash., Sept. 18 ... today extended its Edifecs5010(TM) Compliance S ... Comparison Manual , a comprehensive version analysis resource that ... changes and includes valuable insights from Subject Matter Experts illuminating ...
Cached Medicine News:Health News:Gateway Responding To Increased Need for Treatment Among Middle-Income Substance Abusers 2Health News:Suicides Higher in Rural Areas With Bars 2Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 2Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 3Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 4Health News:Accera, Inc. to Present at UBS Global Life Sciences Conference 2Health News:Statement From Stuart L. Weinstein, MD, Chairman, Doctors for Medical Liability Reform on Senator Baucus' Health Care Reform Proposal 2Health News:Edifecs Extends Its Edifecs5010(TM) Compliance Suite with the Launch of the Edifecs5010(TM) Comparison Manual, a Comprehensive Version Analysis Resource for HIPAA 5010 Migration. 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: